Evaluating Quality of Life in Systemic Lupus Erythematosus: Modern Approaches and Perspectives
Vol. 32 No. 4 (2024), Review articles
Vol. 32 No. 4 (2024)

Evaluating Quality of Life in Systemic Lupus Erythematosus: Modern Approaches and Perspectives

Review articles
https://doi.org/10.35465/32.4.2024.pp41-54
Published May 1, 2025
Daliya Tsvetanova Pencheva
Medical University of Sofia
Dimitar Bakalov
Department of Physiology and Pathophysiology, Medical University of Sofia
Vladimira Boyadzhieva
1.Clinic of Rheumatology, University Clinical Hospital “St. Ivan Rilski”, Sofia 2.Department of Rheumatology, Medical University of Sofia
Mariana Ivanova
1.Clinic of Rheumatology, University Clinical Hospital “St. Ivan Rilski”, Sofia 2.Department of Rheumatology, Medical University of Sofia
Nikolay Stoilov
1.Clinic of Rheumatology, University Clinical Hospital “St. Ivan Rilski”, Sofia 2.Department of Rheumatology, Medical University of Sofia
PDF ENG
PDF BG (Български)

Keywords

Keywords: Systemic Lupus Erythematosus (SLE), Quality of Life (QoL), Lupus-Specific Questionnaires

How to Cite

Pencheva, D., Bakalov, D., Boyadzhieva, V., Ivanova, M., & Stoilov, N. (2025). Evaluating Quality of Life in Systemic Lupus Erythematosus: Modern Approaches and Perspectives. Rheumatology (Bulgaria), 32(4), 41-54. https://doi.org/10.35465/32.4.2024.pp41-54
ACM ACS APA ABNT Chicago Harvard IEEE MLA Turabian Vancouver

Download Citation

Endnote/Zotero/Mendeley (RIS) BibTeX

Abstract

Abstract: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with diverse clinical manifestations. Timely diagnosis and accurate assessment of disease activity are essential for determining optimal therapeutic strategies for each patient. Over recent decades, the prognosis for SLE patients has significantly improved. However, even with proper treatment and remission, quality of life (QoL) remains substantially impaired. This underscores the importance of evaluating health-related quality of life (HRQoL) as part of a comprehensive approach to managing SLE patients. A holistic understanding of a patient`s overall condition involves not only physical health but also psychological and social well-being. In recent years, numerous QoL questionnaires have been increasingly utilized in rheumatological practice. Generic questionnaires, such as the Short Form-36 (SF-36), facilitate comparisons across different diseases but may lack sensitivity to the specific clinical symptoms of SLE. Conversely, lupus-specific questionnaires, including LupusQoL, SLEQOL, LupusPRO, and L-QoL, offer more precise insights by capturing multiple aspects of the disease from the patient`s perspective. Current guidelines emphasize the need to integrate HRQoL assessments into routine clinical practice and research. The literature review highlights the growing role of lupus-specific questionnaires in clinical trials and raises the critical question of their effectiveness and applicability in daily practice to improve medical care.

https://doi.org/10.35465/32.4.2024.pp41-54
PDF ENG
PDF BG (Български)

References

  1. Kaul A, Gordon C, Crow MK et al. Systemic lupuserythematosus. Nat Rev Dis Primers. 2016 Jun 16;2:16039.
  2. Arnaud L, Tektonidou MG. Long-term outcomes in systemic lupuserythematosus: trends over time and major contributors. Rheumatology (Oxford). 2020 Dec 5;59(Suppl5):v29-v38.
  3. Felten R, Scherlinger M, Mertz P et al. New biologics and targeted therapies in systemic lupus: From new molecular targets to new indications. A systematic review, Joint Bone Spine, Volume 90,Issue 2, 2023,105523.
  4. Robl R, Eudy A, Bachali PS, et al. Molecular endotypes of type 1 and type 2 SLE Lupus Science & Medicine
  5. ;10:e000861.
  6. van Vollenhoven RF, Bertsias G, Doria A et al 2021 DORIS defi nition of remission in SLE: fi nal recommendations from an international task force Lupus Science & Medicine 2021;8.
  7. Franklyn K, Lau CS, Navarra SV et al. Defi nition and initial validation of a Lupus Low Disease Activity State (LLDAS) Annals of the Rheumatic Diseases 2016;75:1615-1621.
  8. Fanouriakis A, Kostopoulou M, Andersen J et al. EULAR recommendations for the management of systemic lupuserythematosus: 2023 update Annals of the RheumaticDiseases 2024;83:15-29.
  9. Van Vollenhoven RF, Mosca M, Bertsias G et al. Treatto-target insystemic lupus erythematosus: recommendations fromaninternational task force. Ann Rheum Dis. 2014 Jun;73(6):958-67. doi:10.1136/annrheumdis-2013-205139.
  10. Dua AB, Touma Z, Toloza S, et al. Top 10 recent developments in health-related quality of life in patients with systemic lupus erythematosus. Curr Rheumatol Rep. 2013;15:380.
  11. Mahieu M, Yount S, Ramsey-Goldman R. Patient-reported out comes in systemic lupus erythematosus. Rheum Dis Clin North Am. 2016;42:253–263.
  12. Castelino M, Abbott J, McElhone K, et al. Comparison of the psychometric properties of health-related quality of life measures used in adults with systemic lupus erythematosus: a review of the literature. Rheumatology (Oxford).2013;52:684–696.
  13. Ware JE, Sherbourne CD, The MOS. 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30:473–483.
  14. Gordon C, Amissah-Arthur MB, Gayed M et al. for the British Society for Rheumatology Standards, Audit and Guidelines Working Group, The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults, Rheumatology, Volume 57, Issue 1, January 2018, e1- e45.
  15. Jolly M. How does quality of life of patients with systemic lupus erythematosus compare with that of other common chronic illnesses? J Rheumatol. 2005;32:1706–1708.
  16. Kuriya B, Gladman DD, Ibanez D, et al. Quality of life over time in patients with systemic lupus erythematosus. Arthritis Rheum. 2008;59:181–185
  17. Urowitz M, Gladman DD, Ibanez D, et al. Changes in quality of life in the fi rst 5 years of disease in a multicenter cohort of patients with systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2014;66:1374–1379.
  18. Furie R, Khamashta M, Merrill JT et al. Anifrolumab, an Anti-Interferon-α Receptor Monoclonal Antibody, in Moderate- to-Severe Systemic Lupus Erythematosus. Arthritis Rheumatol. 2017 Feb;69(2):376-386.
  19. Touma Z, Gladman DD, Ibanez D, et al. Is there an advantage over SF-36 with a quality of life measure that is
  20. specific to systemic lupus erythematosus? J Rheumatol.2011;38:1898–1905.
  21. McElhone K, Abbott J, Shelmerdine J, et al. Development and validation of a disease-specifi c health-related quality of life measure, the LupusQoL, for adults with systemic lupus erythematosus. Arthritis Rheum. 2007;57:972–979
  22. Doward LC, McKenna SP, Whalley D, et al. The development of the L-QoL: a quality-of-life instrument specifi c to systemic lupus erythematosus. Ann Rheum Dis. 2009;68:196–200.
  23. Kernder A, Richter JG, Fischer-Betz R, et al. Quality of care predicts outcome in systemic lupus erythematosus: a cross-sectional analysis of a German long-term study (LuLa cohort). Lupus. 2020;29(2):136-143.
  24. Stewart AL, Hays RD, Ware JE Jr. The MOS short-form general health survey. Reliability and validity in a patient population. Med Care 1988; 26: 724-735.
  25. Brazier J, Usherwood T, Harper R, et al. Deriving a preference- based single index from the UK SF-36 Health Survey. J Clin Epidemiol. 1998;51:1115–1128.
  26. Aggarwal R, Wilke CT, Pickard AS, et al. Psychometric properties of the EUROQOL-5D and short form-6D in patients with systemic lupus erythematosus. J Rheumatol. 2009;36:1209–1216.
  27. Fernandez M, Gs A, McGwin G Jr, et al. Using the Short Form 6D, as an overall measure of health, to predict damage accrual and mortality in patients with systemic lupus erythematosus: XLVII, results from a multiethnic US cohort. Arthritis Rheum. 2007;57:986–992.
  28. Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQoL group. Ann Med. 2001;33:337–343.
  29. Ariza-Ariza R, Hernandez-Cruz B, Navarro-Sarabia F. Euro- QoL is a useful instrument for assessing the health-related quality of life of the patients with systemic lupus erythematosus.Lupus. 2005;14:334–335.
  30. Cella D, Riley W, Stone A, et al. The Patient-Reported Outcomes Measurement Information System (PROMIS)
  31. developed and tested its fi rst wave of adult self-reported health outcome item banks: 2005-2008. J Clin Epidemiol. 2010;63:1179–1194.
  32. Kasturi S, Szymonifka J, Burket JC, et al. Feasibility, validity, and reliability of the 10-item Patient Reported Outcomes Measurement Information System Global Health Short Form in outpatients with systemic lupus erythematosus. J Rheumatol. 2018;45:397–404.
  33. Jones JT, Carle AC, Wootton J, et al. Validation of Patient-Reported Outcomes Measurement Information System Short Forms for use in childhood-onset systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2017;69:133–142.
  34. Kosinski M, Gajria K, Fernandes AW, Cella D. Qualitative validation of the FACIT-fatigue scale in systemic lupus erythematosus. Lupus. 2013 Apr;22(5):422-30.
  35. Williams-Hall R, Berry P, Williamson N, et al. Generation of evidence supporting the content validity of SF-36, FACIT-F, and LupusQoL, and novel patient-reported symptom items for use in patients with systemic lupus erythematosus (SLE) and SLE with lupus nephritis (LN). Lupus Science & Medicine 2022;9:e000712.
  36. Gomez A, Qiu V, Cederlund A, et al. Adverse Health-Related Quality of Life Outcome Despite Adequate Clinical Response to Treatment in Systemic Lupus Erythematosus. Front Med (Lausanne). 2021 Apr 16;8:651249.
  37. Kawka L, Sarmiento-Monroy JC, Mertz P et al. Assessment and personalised advice for fatigue in systemic lupus erythematosus using an innovative digital tool: the Lupus Expert system for the Assessment of Fatigue (LEAF) study. RMD Open. 2023 Dec 6;9(4):e003476.
  38. Krupp LB, LaRocca, NG, Muir-Nash, J et al. The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Archieves of Neurology, 46, 1121-1123.).
  39. Düsing C, Chehab G, Richter J et al. Developing a cause diff erentiation of fatigue in patients with systemic lupus erythematosus (SLE) – Aa retrospective single centre analysis 10.1136/lupus-2018-abstract.201
  40. Jolly M, Pickard AS, Wilke C, et al. Lupus-specifi c health outcome measure for US patients: the LupusQoL-US version. Ann Rheum Dis. 2010;69:29–33.
  41. Gonzalez-Rodriguez V, Peralta-Ramirez MI, Navarrete-Navarrete N, et al. Adaptation and validation of the Spanish version of a disease- specifi c quality of life measure in patients with systemic lupus erythematosus: the lupus quality of life. Med Clin (Barc). 2010;134:13–16.
  42. Yazdany J. Health-related quality of life measurement in adult systemic lupus erythematosus: Lupus Quality of Life (LupusQoL), Systemic Lupus Erythematosus-Specifi c Quality of Life Questionnaire (SLEQOL), and systemic lupus erythematosus Quality of Life Questionnaire (L-QoL). Arthritis Care Res (Hoboken). 2011;63(Suppl 11):S413–9.
  43. Jolly M, Pickard AS, Block JA, et al. Disease-specifi c patient reported outcome tools for systemic lupus erythematosus. Semin Arthritis Rheum. 2012;42:56–65.
  44. Azizoddin DR, Weinberg S, Gandhi N, et al. Validation of the LupusPRO version 1.8: an update to a disease-specifi c patient reported outcome tool for systemic lupus erythematosus. Lupus. 2018;27:728–737.
  45. Azizoddin DR, Olmstead R, Cost C et al. A multi-group confirmatory factor analyses of the LupusPRO between southern California and Filipino samples of patients with systemic lupus erythematosus. Lupus. 2017 Aug;26(9):967-974.
  46. Pinto B, Jolly M, Dhooria A et al. LupusPRO: cross cultural validation of disease specifi c patient reported outcome measure of lupus. Lupus. 2019 Nov;28(13):1534-1540.
  47. Jolly M, Garris CP, Mikolaitis RA et al. Development and validation of the Lupus Impact Tracker: a patient-completed tool for clinical practice to assess and monitor the impact of systemic
  48. lupus erythematosus. Arthritis Care Res (Hoboken). 2014;66(10):1542–50.
  49. Leong KP, Kong KO, Thong BY, et al. Development and preliminary validation of a systemic lupus erythematosus-specific quality-of-life instrument (SLEQOL). Rheumatology (Oxford). 2005;44:1267–1276.
  50. Pencheva DT, Coff ey A, McKenna SP et al. Adaptation and validation of the Bulgarian version of the Systemic Lupus Erythematosus Quality of Life Questionnaire (L-QoL). Clin Rheumatol. 2023 Jul;42(7):1811-1817
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Downloads

Download data is not yet available.

Most read articles by the same author(s)